Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 22.00
- Piotroski Score 1.00
- Grade Perform
- Symbol (ISEE)
- Company IVERIC bio, Inc.
- Price $39.95
- Changes Percentage (0.38%)
- Change $0.15
- Day Low $39.85
- Day High $39.98
- Year High $39.99
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 07/23/2023
- Fiscal Year End N/A
- Average Stock Price Target $34.50
- High Stock Price Target $35.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.78
- Trailing P/E Ratio -22.443820224719
- Forward P/E Ratio -22.443820224719
- P/E Growth -22.443820224719
- Net Income $-175,745,000
Income Statement
Quarterly
Annual
Latest News of ISEE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Court orders Leo's Coney Island franchisee to pay overtime, keep accurate timecards
The operator of Leo's Coney Island franchise locations in Michigan has been ordered to maintain accurate employee timecards and pay overtime wages by the U.S. Department of Labor. Violations led to a ...
By Yahoo! Finance | 3 months ago -
Antitrust Regulator Tells Chains: Back Off Your Franchisees
The Federal Trade Commission has advised brands against silencing small business operators or imposing undisclosed fees after a yearlong investigation into franchising conflicts. This move aims to pro...
By The New York Times | 3 months ago -
California fast food workers now earn $20 per hour. Franchisees are responding by cutting hours.
Lawrence Cheng, a Wendy's franchise owner, faces challenges due to increased labor costs after California raised fast food workers' hourly wage. Despite concerns, some operators have adapted by cuttin...
By Yahoo! Finance | 3 months ago
